Sylvia Cheung to Step Down in August 2020 Company Initiates Search for Successor BEDFORD, Mass. , June 02, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products across the orthopedic early
BEDFORD, Mass. --(BUSINESS WIRE)--May 12, 2020-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company, today announced that Cheryl R. Blanchard , Ph.D., President and Chief Executive Officer, and Sylvia Cheung , Chief Financial Officer,
Total Revenue Increases 43% Year-over-Year Continued Progress on Integration of Parcus Medical and Arthrosurface Acquisitions Withdrawing Full Year 2020 Financial Guidance Well Positioned to Manage through COVID-19 Pandemic BEDFORD, Mass. , May 07, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc.
Seasoned industry executive with experience leading global joint preservation and restoration businesses BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 27, 2020-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its
BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 23, 2020-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its first quarter 2020 financial results after the close of the market on Thursday, May 7, 2020 and hold its investor conference call on the same day, Thursday,
BEDFORD, Mass. , April 08, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (“HA”) technology platform , today provided an update on actions it is
Seasoned executive brings extensive experience leading corporate legal and governance teams BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid
Total Revenue Increases 10% Year-over-Year for the Fourth Quarter Completes Acquisitions of Parcus Medical and Arthrosurface Company Expects Total Revenue Growth in the 40% to 44% Range for Full Year 2020 BEDFORD, Mass. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc.
BEDFORD, Mass. , Feb. 12, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that Dr. Cheryl Blanchard , a member of the Company’s Board of Directors since August 2018 , has been named interim Chief Executive Officer, effective immediately, while the Board continues
BEDFORD, Mass. --(BUSINESS WIRE)--Feb. 6, 2020-- First paragraph, first sentence should read: Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its fourth-quarter and full-year 2019 financial results after the close of the market on Thursday, February 20, 2020
